Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
The present invention is drawn to methods and compositions for treating inflammatory disorders of the lower airways, comprising administering an effective amount of an agent, which modulates the expression and/or activity of a proinflammatory cytokine or fragment thereof, preferably in a human. The proinflammatory cytokine contemplated by the invention includes IL-1, IL-6, IL-8 and TNF-alpha. The present invention describes a kit comprising a delivery device and a pharmaceutical composition for administration of the agent. The pharmaceutical composition includes at least one proinflammatory cytokine inhibitor, optionally one or more additional active ingredients, and at least one pharmaceutically active carrier. The delivery device further comprises a nebulizer, an inhaler, a powder dispenser, an intrapulmonary aerosolizer and a sub-miniature aerosolizer.
1. A kit comprising:
a delivery device suitable for direct administration of a pharmaceutical composition to lower airways; and
an effective amount of an agent comprising an IL-1 receptor antagonist that is anakinra in a form of a particle of less than 10 microns.
2. The kit according to claim 1 , wherein the delivery device is capable of delivering the effective amount of the agent and the at least one pharmaceutically acceptable carrier to the lower airways via inhalation.
3. The kit according to claim 1 , wherein the delivery device is capable of delivering the effective amount of the agent and the at least one pharmaceutically acceptable carrier to the lower airways via direct instillation.
4. The kit according to claim 2 , wherein the delivery device is capable of delivering an effective aerosol of the agent and the at least one pharmaceutically acceptable carrier to the lower airways via inhalation.
5. The kit according to claim 4 , wherein the delivery device is selected from the group consisting of a nebulizer, an inhaler, or a subminiature aerolizer.
6. The kit according to claim 5 , wherein the delivery device is capable of delivering a liquid or suspension.
7. The kit according to claim 5 , wherein the delivery device is a jet nebulizer.
8. The kit according to claim 5 , wherein the delivery device is an ultrasonic nebulizer.
9. The kit according to claim 5 , wherein the delivery device is a metered dose inhaler.
10. The kit according to claim 5 , wherein the delivery device is a dry powder inhaler.
11. The kit according to claim 3 , wherein the delivery device is capable of delivering an effective aerosol of agent and pharmaceutical carrier to the lower airways via direct instillation.
12. The kit according to claim 11 , wherein the delivery device is selected from the group consisting of an intrapulmonary aerolizer, a sprayer, or subminiature aerolizer.
13. The kit according to claim 12 , wherein the delivery device is capable of delivering a liquid or suspension.
14. The kit according to claim 12 , wherein the delivery device is capable of delivering a dry powder.
15. The kit according to claim 1 , wherein the effective agent is supplied in a container closure.
16. The kit according to claim 15 , wherein the container is a prefilled syringe.
17. The kit according to claim 16 , wherein the prefilled syringe is glass.
18. The kit according to claim 16 , wherein the prefilled syringe is labeled.
19. The kit according to claim 15 , wherein the container is a vial.
20. The kit according to claim 19 , wherein the vial is glass.
21. The kit according to claim 19 , wherein the vial is labeled.
22. The kit according to claim 1 , comprising instructions for use of an effective agent.
23. The kit according to claim 1 , comprising a package insert describing use of the effective agent.
24. The kit according to claim 2 , wherein the delivery device is a breath actuated nebulizer.
25. The kit according to claim 1 , where the effective amount of the agent is between 100 micrograms and 50 mg.
26. The kit according to claim 25 , where a dose of the agent is a daily dose, administered at least once-a-day.
27. The kit according to claim 1 , wherein the particle is of 3 to 5 microns.
28. The kit according to claim 1 , wherein the delivery device is suitable for direct administration of the pharmaceutical composition to bronchioles.
29. The kit according to claim 1 , wherein the delivery device is suitable for direct administration of the pharmaceutical composition to alveolar tissue.